Elvitegravir

19 interactions 1 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Levonorgestrel Intrauterine System Ketoconazole Topical Dexamethasone Ophthalmic Orlistat Estradiol Medroxyprogesterone Injection
18 Major 1 Moderate
All (19) Major (18) Moderate (1)

Major

Elvitegravir Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Elvitegravir Dexamethasone Injection Decadron Decreased elvitegravir concentrations resulting in reduced virologic response and possible viral resistance; increased risk of Cus... Details Elvitegravir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Decreased elvitegravir concentrations resulting in reduced virologic response and possible viral resistance; increased risk of Cus... Details Elvitegravir Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Elvitegravir Estradiol Delestrogen Altered contraceptive effectiveness and risk of side effects Details Elvitegravir Estradiol Topical Divigel Altered contraceptive effectiveness and risk of side effects Details Elvitegravir Estradiol Transdermal Patch Alora® Altered contraceptive effectiveness and risk of side effects Details Elvitegravir Ketoconazole Topical Extina® Foam Increased elvitegravir exposure and an increased ketoconazole exposure Details Elvitegravir Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Elvitegravir Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Elvitegravir Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Elvitegravir Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Elvitegravir Levonorgestrel After banger Altered contraceptive effectiveness and risk of side effects Details Elvitegravir Levonorgestrel Intrauterine System Kyleena Altered contraceptive effectiveness and risk of side effects Details Elvitegravir Medroxyprogesterone Amen® Altered contraceptive effectiveness and risk of side effects Details Elvitegravir Medroxyprogesterone Injection Depo-Provera Altered contraceptive effectiveness and risk of side effects Details Elvitegravir Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Elvitegravir Orlistat Alli Reduced efficacy of antiretrovirals, loss of virological control Details

Moderate

Elvitegravir Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.